PFE Pfizer Inc.

Tim Buckley Elected to Pfizer’s Board of Directors

Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer’s Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent.

Mr. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024. Previously he was Vanguard’s Chief Investment Officer, overseeing the company’s internally managed stock, bond and money market portfolios as well as investment research and methodology. Mr. Buckley joined Vanguard in 1991 and held numerous senior leadership roles, including Chief Information Officer and head of the Retail Investor Group. Outside of Vanguard, he served as Chairman of the board of Children’s Hospital of Philadelphia from 2011 to 2017.

Mr. Buckley received a Bachelor of Arts in Economics from Harvard College and a Master of Business Administration from Harvard Business School.

“We are pleased to welcome Tim Buckley to Pfizer’s Board of Directors,” stated Albert Bourla, Pfizer Chairman and Chief Executive Officer. “Tim is a widely respected business leader with deep expertise in global investment management, financial markets, and operations and someone who values a shared sense of purpose, all of which will be an asset to Pfizer and our shareholders.”

“I'm honored to join Pfizer’s Board of Directors, a group of leaders with distinguished careers in science, government, academia, technology and business,” said Buckley. “I'm impressed with Pfizer’s dedication to patients and focus on innovation to improve health. I look forward to working with the Board and management to support the breakthroughs that change patients' lives while concurrently driving long-term shareholder value.”

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on X at and and like us on Facebook at .

Category: Corporate

EN
15/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pfizer Inc.

 PRESS RELEASE

Pfizer Announces New Chief Scientific Officer and President, Research ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff will remain a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Of...

 PRESS RELEASE

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII

 PRESS RELEASE

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussi...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion w...

 PRESS RELEASE

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussi...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief U.S. Commercial Officer, Executive Vice President, at the UBS Global Healthcare Conference on Wednesday, November 13, 2024 at 12:30 p.m. PST. To view and listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after the end of the live...

 PRESS RELEASE

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guida...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance(1) for both Revenues and Adjusted(2) diluted EPS. The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at . EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another strong quarter of results as we continued to execute with discipline, strengthen our commercial position and advance our ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch